7-Heptyl-3-methyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 7-Heptyl-3-methyl-8-piperazin-1-yl-3,7-dihydro-purine-2,6-dione
• 英文别名: 7-heptyl-3-methyl-8-(piperazin-1-yl)-3,7-dihydro-1H-purine-2,6-dione；7-heptyl-3-methyl-8-piperazin-1-ylpurine-2,6-dione
• 化学式: C₁₇H₂₈N₆O₂
• 分子量: 348.448
• InChiKey: GHMYMBNVKKTJGK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  25
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  82.5
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  哌嗪 、 8-bromo-7-heptyl-3-methyl-3,7-dihydro-1H-purine-2,6-dione 以92%的产率得到
  参考文献：
  名称：

  POMAHEHKO M. I.; FEDULOVA I. V.; PRIJMENKO B. O.; ORESTENKO L. P.SINTEZ T+, FARMATS. ZH.,(1986) N 5, 41-44, 80

  摘要：

  DOI：

文献信息

• Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV
  申请人：——

  公开号：US20020161001A1

  公开（公告）日：2002-10-31

  The present invention relates to therapeutically active and selective inhibitors of the enzyme DPP-IV, pharmaceutical compositions comprising the compounds and the use of such compounds for and the manufacture of medicaments for treating diseases that are associated with proteins which are subject to inactivation by DPP-IV, such as type 2 diabetes and obesity, as well as methods for treating diseases that are associated with proteins which are subject to inactivation by DPP-IV, such as type 2 diabetes and obesity

  本发明涉及治疗活性和选择性抑制剂酶DPP-IV，包含该化合物的药物组合物以及利用这些化合物制造用于治疗与DPP-IV使蛋白质失活有关的疾病的药物，例如2型糖尿病和肥胖症，以及治疗与DPP-IV使蛋白质失活有关的疾病的方法，例如2型糖尿病和肥胖症。
• Method and composition for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states
  申请人：——

  公开号：US20030236272A1

  公开（公告）日：2003-12-25

  The present invention is related to a method and composition for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states comprising administering inhibitors of the enzymes NEP and DPP-IV to individuals suffering from one or more of those conditions. Inhibition of the activity of the two enzymes will potentiate the insulin releasing activity of endogenous GLP-1 and other DPP-IV substrates like GIP.

  本发明涉及一种治疗糖尿病、高血压、慢性心力衰竭和液体潴留状态的方法和组合物，包括向患有这些疾病中的一个或多个的个体中施用NEP和DPP-IV酶抑制剂。抑制这两种酶的活性将增强内源性GLP-1和其他DPP-IV底物如GIP的胰岛素释放活性。
• Heterocyclic compounds that are inhibitors of the enzyme DPP-IV
  申请人：NOVO NORDISK A/S

  公开号：EP1561752A1

  公开（公告）日：2005-08-10

  The present invention relates to therapeutically active and selective inhibitors of the enzyme DPP-IV, pharmaceutical compositions comprising the compounds and the use of such compounds for and the manufacture of medicaments for treating diseases that are associated with proteins which are subject to inactivation by DPP-IV, such as type 2 diabetes and obesity, as well as methods for treating diseases that are associated with proteins which are subject to inactivation by DPP-IV, such as type 2 diabetes and obesity.

  本发明涉及具有治疗活性和选择性的DPP-IV酶抑制剂、包含这些化合物的药物组合物、使用这些化合物治疗与DPP-IV灭活的蛋白质有关的疾病（如2型糖尿病和肥胖症）的药物以及治疗与DPP-IV灭活的蛋白质有关的疾病（如2型糖尿病和肥胖症）的方法。
• HETEROCYCLIC COMPOUNDS, WHICH ARE INHIBITORS OF THE ENZYME DPP-IV
  申请人：NOVO NORDISK A/S

  公开号：EP1301187A2

  公开（公告）日：2003-04-16
• METHOD AND COMPOSITION FOR TREATMENT OF DIABETES, HYPERTENSION, CHRONIC HEART FAILURE AND FLUID RETENTIVE STATES
  申请人：NOVO NORDISK A/S

  公开号：EP1496877B1

  公开（公告）日：2008-10-01